Alexander Kutikov, MD, FACS

A. Kutikov, MD, FACS

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111


Professor, Department of Surgical Oncology

Kidney, Bladder, and Prostate Cancer TRDG Member

American Urological Association's Prostate Health Committee Panel Member

Treatment Focus

Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery

Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.

Research Program

Key Awards

  • America's Top Doctors®2016-2017
  • Philadelphia Magazine Top Doctors, 2017

Language(s) Other than English


Treatment Philosophy

I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.

When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.

As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.

Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.

Education, Training & Credentials

Educational Background

  • Fellow, Society of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Chief Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2007-2008
  • Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2004-2007
  • MD, Harvard Medical School, Harvard-MIT Health Sciences and Technology Program, Boston, MA, 2003


  • American Board of Urology, Board Certified


  • Society of Urologic Oncology
  • American Urological Association
  • American College of Surgeons
  • Philadelphia Urological Society

Honors & Awards

  • CaPSURE Scholar, CaPSURE Scholars Program in Prostate Cancer Outcomes Research, 2009-10
  • American College of Surgeons Excellence in Research Award 96th Annual Clinical Congress, Surgical Forum, 2010
  • Mid-Atlantic AUA Young Investigator Representative to the AUA’s Research Forum, American Urological Association Meeting, Washington, DC, 2011
  • BJU International Journal Best Mobile App Award for drawMD Urology iPad Application, American Urological Association Meeting, San Diego, CA, 2013
  • America's Top Doctors®, 2016-2017
  • Philadelphia Magazine Top Doctors, 2017
Patient Stories

Joe Briggs

Prostate Cancer

Joe Briggs

Prostate Cancer

When Joe Briggs, Jr. turned 50 in 2013, his wife of 24 years, Valerie, urged him to make an appointment with his primary doctor for a complete physical and a blood work-up. At the time the only health concern Joe had experienced was frequent urination, often at night. “I was healthy, active, wasn’t super overweight. I just attributed the urination issues to getting older,” he said. Blood work from the physical revealed an elevated prostate-specific antigen (PSA) which was 7.1. 

Victoria Mirarchi


Victoria Mirarchi


In early 2013, Victoria Mirarchi, who was very active and healthy at the age of 81, underwent a surgical procedure at her local hospital to remove a very large mass from her abdominal area. The pathology confirmed a diagnosis of liposarcoma. The tumor was aggressive and returned the following year. In mid-2014 Victoria was admitted to the hospital for another procedure, which was followed by 7 weeks of radiation therapy.

Andrew Swider

Kidney Cancer

Andrew Swider

Kidney Cancer

A Vietnam veteran with experience on the battlefront, Andrew Swider knows one thing for sure. “There’s nobody I’d rather have in the foxhole with me than Dr. Kutikov.”

Arkady Shteyman

Kidney Cancer

Arkady Shteyman

Kidney Cancer

Kidney cancer is something Arkady Shteyman has lived with since 1968. That's the year, when Arkady was 19, that his father died of the disease at the young age of 44.

"Because I have that history, I get regular ultrasounds," said the electronic technician, who immigrated to the Philadelphia region from the Ukraine in the former Soviet Union in 1990.

Bil Sauer

Kidney Cancer

Bil Sauer

Kidney Cancer

In June, 2012, Bil Sauer, an entrepreneur and owner of several businesses, was wrapping up a busy work week. It was late afternoon on a Friday, and his wife Laura and he were planning on spending the weekend at their lake home with their two teenage children Tom, 14, and Tehya, 18. “It was getting late so I told my wife and kids to go ahead and I would meet them there,” recalls Bil. He lost track of time and it was almost 7:00 pm before he left his Bucks County office. Bil decided he would drive up on Saturday morning instead.


Research Profile

Research Program

Research Interests

Dr. Kutikov has authored over 140 peer-reviewed publications.  His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks.  He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.

Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care.  He is a co-founder of several ventures that strive to improve physician education and patient care.  

Lab Overview

In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.

As part of our work, we explore the role of zinc in development and progression of prostate malignancy.  Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.

The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.

In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.


Selected Publications

S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015.   PubMed

J. J. Tomaszewski, R. G. Uzzo, B. Egleston, A. T. Corcoran, R. Mehrazin, D. M. Geynisman, J. A. Ridge, C. Veloski, N. Kocher, M. C. Smaldone, and A. Kutikov, “Coupling of Prostate and Thyroid Cancer Diagnoses in the United States.,” Ann Surg Oncol, pp. 1–7, Sep. 2014.   PubMed

A. T. Corcoran, S. D. Kaffenberger, P. E. Clark, J. Walton, E. Handorf, Z. Piotrowski, J. J. Tomaszewski, S. Ginzburg, R. Mehrazin, E. Plimack, D. Y. T. Chen, M. C. Smaldone, R. G. Uzzo, T. M. Morgan, and A. Kutikov, “Hypoalbuminemia is Associated with Mortality in Patients Undergoing Cytoreductive Nephrectomy.,” BJU Int, pp. n/a–n/a, Aug. 2014.  

J. J. Tomaszewski, M. C. Smaldone, R. G. Uzzo, and A. Kutikov, “Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephron-sparing surgery?,” BJU Int, pp. n/a–n/a, Aug. 2014.   PubMed

A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014.    PubMed

B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity.,” European Urology, May 2014.   PubMed

S. Ginzburg, R. Uzzo, T. Al-Saleem, E. Dulaimi, J. Walton, A. Corcoran, E. Plimack, R. Mehrazin, J. Tomaszewski, R. Viterbo, D. Y. T. Chen, R. Greenberg, M. Smaldone, and A. Kutikov, “Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy.,” The Journal of Urology, vol. 191, no. 2, pp. 296–300, Feb. 2014.    PubMed

A. Kutikov, B. L. Egleston, D. Canter, M. C. Smaldone, Y.-N. Wong, and R. G. Uzzo, “Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model.,” The Journal of Urology, vol. 188, no. 6, pp. 2077–2083, Dec. 2012.    PubMed

M. C. Smaldone, B. Egleston, R. G. Uzzo, and A. Kutikov, “Does partial nephrectomy result in a durable overall survival benefit in the Medicare population?,” The Journal of Urology, vol. 188, no. 6, pp. 2089–2094, Dec. 2012.    PubMed

A. Kutikov, B. Rozenfeld, B. L. Egleston, M. Sirohi, R. W. Hwang, and R. G. Uzzo, “Academic ranking score: a publication-based reproducible metric of thought leadership in urology.,” European Urology, vol. 61, no. 3, pp. 435–439, Mar. 2012.   PubMed

A. Kutikov, K. Mallin, D. Canter, Y.-N. Wong, and R. G. Uzzo, “Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database.,” The Journal of Urology, vol. 186, no. 3, pp. 805–810, Sep. 2011.    PubMed

A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011.   PubMed

A. Kutikov, Z. J. Piotrowski, D. J. Canter, T. Li, D. Y. T. Chen, R. Viterbo, R. E. Greenberg, S. A. Boorjian, and R. G. Uzzo, “Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal gland is radiographically normal.,” The Journal of Urology, vol. 185, no. 4, pp. 1198–1203, Apr. 2011.   PubMed

A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010.   PubMed

A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth.,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009.    PubMed

Additional Publications